{"id":4927,"date":"2024-07-18T03:41:34","date_gmt":"2024-07-18T07:41:34","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/?post_type=resource&#038;p=4927"},"modified":"2024-08-29T05:58:59","modified_gmt":"2024-08-29T09:58:59","slug":"webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development","status":"publish","type":"resource","link":"https:\/\/cytel.agencyukdev.com\/fr\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/","title":{"rendered":"Webinar &#8211; Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development"},"content":{"rendered":"","protected":false},"featured_media":3713,"template":"","meta":{"_acf_changed":false},"tags":[136],"asset-type":[56],"drug-development-phases":[64,65,66,505],"service-type":[491,486,493,494,523,480],"therapeutic-areas":[58],"class_list":["post-4927","resource","type-resource","status-publish","has-post-thumbnail","hentry","tag-webinar","asset-type-webinars","drug-development-phases-phase-1","drug-development-phases-phase-2","drug-development-phases-phase-3","drug-development-phases-preclinical","service-type-adaptive-trial-design","service-type-bayesian","service-type-modeling","service-type-optimization","service-type-regulatory-affairs","service-type-strategic-consulting","therapeutic-areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Webinar - Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us<\/title>\n<meta name=\"description\" content=\"Key aims in early oncology development are to estimate the recommended Phase 2 dose (RP2D) and investigate which patient populations are optimal for further development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Webinar - Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"og:description\" content=\"Key aims in early oncology development are to estimate the recommended Phase 2 dose (RP2D) and investigate which patient populations are optimal for further development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-29T09:58:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/iStock-1470900662_abstract.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2337\" \/>\n\t<meta property=\"og:image:height\" content=\"1283\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/\",\"url\":\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/\",\"name\":\"Webinar - Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/iStock-1470900662_abstract.jpg\",\"datePublished\":\"2024-07-18T07:41:34+00:00\",\"dateModified\":\"2024-08-29T09:58:59+00:00\",\"description\":\"Key aims in early oncology development are to estimate the recommended Phase 2 dose (RP2D) and investigate which patient populations are optimal for further development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/iStock-1470900662_abstract.jpg\",\"contentUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/iStock-1470900662_abstract.jpg\",\"width\":2337,\"height\":1283,\"caption\":\"abstract vector background with hexagons. 3d design\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/resource\\\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Webinar &#8211; Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\",\"name\":\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"description\":\"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Webinar - Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Key aims in early oncology development are to estimate the recommended Phase 2 dose (RP2D) and investigate which patient populations are optimal for further development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/","og_locale":"fr_FR","og_type":"article","og_title":"Webinar - Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","og_description":"Key aims in early oncology development are to estimate the recommended Phase 2 dose (RP2D) and investigate which patient populations are optimal for further development.","og_url":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/","og_site_name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","article_modified_time":"2024-08-29T09:58:59+00:00","og_image":[{"width":2337,"height":1283,"url":"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/iStock-1470900662_abstract.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/","url":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/","name":"Webinar - Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","isPartOf":{"@id":"https:\/\/cytel.agencyukdev.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/#primaryimage"},"image":{"@id":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/iStock-1470900662_abstract.jpg","datePublished":"2024-07-18T07:41:34+00:00","dateModified":"2024-08-29T09:58:59+00:00","description":"Key aims in early oncology development are to estimate the recommended Phase 2 dose (RP2D) and investigate which patient populations are optimal for further development.","breadcrumb":{"@id":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/#primaryimage","url":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/iStock-1470900662_abstract.jpg","contentUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/iStock-1470900662_abstract.jpg","width":2337,"height":1283,"caption":"abstract vector background with hexagons. 3d design"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytel.com\/resource\/webinar-project-optimus-dose-escalation-and-stratification-designs-in-early-oncology-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cytel.agencyukdev.com\/"},{"@type":"ListItem","position":2,"name":"Webinar &#8211; Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development"}]},{"@type":"WebSite","@id":"https:\/\/cytel.agencyukdev.com\/#website","url":"https:\/\/cytel.agencyukdev.com\/","name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cytel.agencyukdev.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/resource\/4927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/types\/resource"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media\/3713"}],"wp:attachment":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media?parent=4927"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/tags?post=4927"},{"taxonomy":"asset-type","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/asset-type?post=4927"},{"taxonomy":"drug-development-phases","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/drug-development-phases?post=4927"},{"taxonomy":"service-type","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/service-type?post=4927"},{"taxonomy":"therapeutic-areas","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/therapeutic-areas?post=4927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}